Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 5/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24695810 | 0.88 | HPGD (0.42) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24695637 | 0.88 | HPGD (0.42) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL20064749 | 0.86 | KMO (0.43) | KMT2ASMN1; SMN2KDM4EPSMB8PSMB9 | |
| SCHEMBL20065167 | 0.79 | HPGD (0.52) | NPC1RAB9AKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL24695995 | 0.77 | KDM4E (0.43) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24695813 | 0.77 | KDM4E (0.43) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24695991 | 0.76 | HPGD (0.42) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24695811 | 0.76 | HPGD (0.42) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24695814 | 0.76 | HPGD (0.41) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL24696375 | 0.76 | SMN1; SMN2 (0.40) | CSNK1DNPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-07-16 | — | — | US | disclosed |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2019-08-15 | — | — | US | disclosed |
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2019-02-19 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-19 | — | — | US | disclosed |
| WO-2016174079-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208048-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | CSNK1D 2346/4885NPC1 2620/4885RAB9A 1227/4885 |
| US-20200223855-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | CSNK1D 2346/4885NPC1 2620/4885RAB9A 1227/4885 |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | CSNK1D 2346/4885NPC1 2620/4885RAB9A 1227/4885 |
| US-20180105529-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | CSNK1D 2346/4885NPC1 2620/4885RAB9A 1227/4885 |
| US-20190248793-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | ZC3HAV1, MAVS, TYMP | CSNK1D 2346/4885NPC1 2620/4885RAB9A 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.